Ahmed A Kolkailah

Jan 10, 2025 | onlinelibrary.wiley.com | Ambarish Pandey |Ahmed A Kolkailah |Darren McGuire |Robert Frederich

Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalizations for heart failure (HHF) among high-risk patients with type 2 diabetes (T2D).1-4 In VERTIS CV (NCT01986881), the ertugliflozin cardiovascular (CV) outcome trial in individuals with T2D and atherosclerotic CV disease (ASCVD),5 ertugliflozin was associated with a 30% reduction in the relative risk of first and total adjudication-confirmed HHF.6 However, adjudication-confirmed HHF events may not...